questionsmedicales.fr
États, signes et symptômes pathologiques
Signes et symptômes
Manifestations neurologiques
Paralysie
Ophtalmoplégie
Ophtalmoplégie externe progressive
Syndrome de Kearns-Sayre
Syndrome de Kearns-Sayre : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de Kearns-Sayre : Questions médicales les plus fréquentes",
"headline": "Syndrome de Kearns-Sayre : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndrome de Kearns-Sayre : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-22",
"dateModified": "2025-02-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndrome de Kearns-Sayre"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Ophtalmoplégie externe progressive",
"url": "https://questionsmedicales.fr/mesh/D017246",
"about": {
"@type": "MedicalCondition",
"name": "Ophtalmoplégie externe progressive",
"code": {
"@type": "MedicalCode",
"code": "D017246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.636.447.511"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de Kearns-Sayre",
"alternateName": "Kearns-Sayre Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D007625",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Diego Martinelli",
"url": "https://questionsmedicales.fr/author/Diego%20Martinelli",
"affiliation": {
"@type": "Organization",
"name": "Division of Metabolism, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy."
}
},
{
"@type": "Person",
"name": "Glen Lester Sequiera",
"url": "https://questionsmedicales.fr/author/Glen%20Lester%20Sequiera",
"affiliation": {
"@type": "Organization",
"name": "St. Boniface Hospital Albrechtsen Research Centre, Regenerative Medicine Program, Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, Institute of Cardiovascular Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R2H 2A6, Canada."
}
},
{
"@type": "Person",
"name": "Abhay Srivastava",
"url": "https://questionsmedicales.fr/author/Abhay%20Srivastava",
"affiliation": {
"@type": "Organization",
"name": "St. Boniface Hospital Albrechtsen Research Centre, Regenerative Medicine Program, Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, Institute of Cardiovascular Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R2H 2A6, Canada."
}
},
{
"@type": "Person",
"name": "Keshav Narayan Alagarsamy",
"url": "https://questionsmedicales.fr/author/Keshav%20Narayan%20Alagarsamy",
"affiliation": {
"@type": "Organization",
"name": "St. Boniface Hospital Albrechtsen Research Centre, Regenerative Medicine Program, Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, Institute of Cardiovascular Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R2H 2A6, Canada."
}
},
{
"@type": "Person",
"name": "Cheryl Rockman-Greenberg",
"url": "https://questionsmedicales.fr/author/Cheryl%20Rockman-Greenberg",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics and Child Health, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 3P4, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36600424",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-067251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35617986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2213-2600(22)00088-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39161682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S472651"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36612875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20010552"
}
},
{
"@type": "ScholarlyArticle",
"name": "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35725922",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41591-022-01861-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paralysie",
"item": "https://questionsmedicales.fr/mesh/D010243"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ophtalmoplégie",
"item": "https://questionsmedicales.fr/mesh/D009886"
},
{
"@type": "ListItem",
"position": 7,
"name": "Ophtalmoplégie externe progressive",
"item": "https://questionsmedicales.fr/mesh/D017246"
},
{
"@type": "ListItem",
"position": 8,
"name": "Syndrome de Kearns-Sayre",
"item": "https://questionsmedicales.fr/mesh/D007625"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndrome de Kearns-Sayre - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndrome de Kearns-Sayre",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndrome de Kearns-Sayre",
"description": "Comment diagnostique-t-on le syndrome de Kearns-Sayre ?\nQuels tests génétiques sont utilisés ?\nQuels signes cliniques sont observés ?\nL'électrocardiogramme est-il utile ?\nLes biopsies musculaires sont-elles nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndrome de Kearns-Sayre",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme fréquent ?\nY a-t-il des problèmes de vision ?\nLes troubles de l'équilibre sont-ils possibles ?\nLes patients peuvent-ils avoir des douleurs musculaires ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndrome de Kearns-Sayre",
"description": "Peut-on prévenir le syndrome de Kearns-Sayre ?\nLes tests génétiques peuvent-ils aider ?\nLes conseils génétiques sont-ils utiles ?\nLes femmes enceintes doivent-elles être testées ?\nY a-t-il des recommandations pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndrome de Kearns-Sayre",
"description": "Quel est le traitement principal du syndrome ?\nLes suppléments de coenzyme Q10 sont-ils utiles ?\nDes médicaments sont-ils prescrits pour la cardiomyopathie ?\nLa physiothérapie est-elle recommandée ?\nY a-t-il des traitements pour les troubles de la vision ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndrome de Kearns-Sayre",
"description": "Quelles sont les complications possibles ?\nLe syndrome peut-il affecter la qualité de vie ?\nY a-t-il un risque accru de diabète ?\nLes troubles de la mémoire sont-ils fréquents ?\nLes patients sont-ils à risque d'infections ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndrome de Kearns-Sayre",
"description": "Quels sont les facteurs de risque connus ?\nLe sexe influence-t-il le risque ?\nL'âge d'apparition est-il variable ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes mutations génétiques sont-elles héréditaires ?",
"url": "https://questionsmedicales.fr/mesh/D007625?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on le syndrome de Kearns-Sayre ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, l'IRM et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests génétiques sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour détecter des mutations dans l'ADN mitochondrial sont effectués."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ophtalmoplégie, troubles cardiaques et anomalies neurologiques sont typiques."
}
},
{
"@type": "Question",
"name": "L'électrocardiogramme est-il utile ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut montrer des anomalies cardiaques associées au syndrome."
}
},
{
"@type": "Question",
"name": "Les biopsies musculaires sont-elles nécessaires ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour détecter des anomalies mitochondriales."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ophtalmoplégie, cardiomyopathie, surdité et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme fréquent ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue chronique est courante chez les patients atteints."
}
},
{
"@type": "Question",
"name": "Y a-t-il des problèmes de vision ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles visuels comme la ptose et la rétinopathie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles de l'équilibre sont-ils possibles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes d'équilibre et de coordination peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Les patients peuvent-ils avoir des douleurs musculaires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires et des crampes sont souvent rapportées."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le syndrome de Kearns-Sayre ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, car c'est une maladie génétique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier les porteurs et informer les familles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être testées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si des antécédents familiaux existent, un test peut être recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils sur la gestion des symptômes et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du syndrome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement curatif, mais des soins symptomatiques sont offerts."
}
},
{
"@type": "Question",
"name": "Les suppléments de coenzyme Q10 sont-ils utiles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent aider à améliorer la fonction mitochondriale."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits pour la cardiomyopathie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme les bêtabloquants peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut aider à améliorer la force et la mobilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements pour les troubles de la vision ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des aides visuelles et des interventions chirurgicales peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance cardiaque et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Le syndrome peut-il affecter la qualité de vie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent gravement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent développer un diabète de type 2."
}
},
{
"@type": "Question",
"name": "Les troubles de la mémoire sont-ils fréquents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs et de la mémoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les patients sont-ils à risque d'infections ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une immunité affaiblie peut augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de maladies mitochondriales sont un facteur de risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le syndrome affecte les hommes et les femmes de manière égale."
}
},
{
"@type": "Question",
"name": "L'âge d'apparition est-il variable ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître entre l'enfance et l'âge adulte."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas de preuves solides sur l'influence environnementale."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles héréditaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations peuvent être transmises par la mère à l'enfant."
}
}
]
}
]
}
Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on...
ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud...
The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co...
NCT04990232....
Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p...
In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a...
Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (...
In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi...
National Institute of Allergy and Infectious Diseases....
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile....
This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin...
The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ...
This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec...
www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....
Electroencephalography (EEG) is pivotal in the clinical assessment of epilepsy, and sleep is known to improve the diagnostic yield of its recording. Sleep-EEG recording is generally reached by either ...
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis t...
Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across...
To investigate the safety and tolerability of high-dose UDCA in PD and determine midbrain target engagement....
The UP (UDCA in PD) study was a phase II, randomized, double-blind, placebo-controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The p...
UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain...
High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wile...
To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock....
Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi...
Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ...
In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors....
Prospective registration - trial number ACTRN12617001392358....
Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such...
We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ...
After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ...
The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP....
NCT02958917....
Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou...
We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam...
One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...
We hypothesize that synbiotic supplementation could modulate the intestinal microbiota and subsequently, improve the condition of hypothyroid patients....
Fifty-six adult hypothyroid patients were recruited to this double-blind, placebo-controlled, randomized clinical trial. The intervention was 10 weeks of synbiotic (500 mg of 109 CFU/g probiotics plus...
Analysis on 51 patients who completed the trial showed that TSH and depression (p> 0.05) did not change significantly, while serum FT4 significantly increased in both groups (p = 0.03 and p = 0.02 in ...
Ten-week supplementation with synbiotic had no favorable effect on depression and TSH, but it improved blood pressure and quality of life in patients with hypothyroidism. More trials are needed to sup...
IRCT20210926052583N1, Iranian Registry of Clinical Trials (IRCT), registered October 1st, 2021....